NCT01571635 - Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2012

Primary Completion Date

July 2, 2015

Study Completion Date

May 24, 2022

Conditions

Beta Thalassemia MajorBeta Thalassemia Intermedia

Interventions

DRUG

SOTATERCEPT (ACE-011)

0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Trial Locations (18)

Laiko General Hospital, Ampelokipi - Athens

Local Institution - 200, Genoa

Ospedale Galliera, Genoa

Ente Ospedaliero Ospedali Galliera, Genova

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan

Fondazione IRCCS Ospedale Maggiore, Milan

Local Institution - 201, Milan

Hospital of Necker, Paris

Local Institution - 001, Paris

Hopital Henri Mondor, Créteil

Groupe Hospitalier Henri Mondor, Créteil

Hôpital Necker-Enfants Malades, Paris

Local Institution - 300, Ampelokipi - Athens

Universita degli Studi di Cagliari - ASL8, Cagliari

Universita Degli Studi Di Cagliari, Cagliari

Local Institution - 100, London

UCL Cancer Institute, London

UCL Cancer Institue, London